Results 21 to 30 of about 5,486 (237)

Calcitonin gene-related peptide predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope

open access: yesFrontiers in Neuroscience, 2022
The vasoconstriction agent midodrine hydrochloride is a vital treatment for pediatric patients diagnosed with vasovagal syncope (VVS), although the efficacy is variable.
Lintian Li   +4 more
doaj   +1 more source

Stimulation of Alpha-1-Adrenergic Receptor Ameliorates Obesity-Induced Cataracts by Activating Glycolysis and Inhibiting Cataract-Inducing Factors [PDF]

open access: yesEndocrinology and Metabolism, 2022
Background Obesity, the prevalence of which is increasing due to the lack of exercise and increased consumption of Westernized diets, induces various complications, including ophthalmic diseases. For example, obesity is involved in the onset of cataracts.
Yong-Jik Lee   +8 more
doaj   +1 more source

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies

open access: yesCardiology and Therapy, 2023
Background Studies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results.
Mohamed Hamed   +9 more
doaj   +1 more source

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

open access: yesFrontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Related Dysautonomia in Merkel Cell Carcinoma: A Case Report. [PDF]

open access: yesCancer Rep (Hoboken)
ABSTRACT Background Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory pathways that cancer cells exploit to suppress T‐cell activation. Although immune‐related adverse events (irAEs) linked to ICI therapy are well documented and encompass dermatologic, endocrine, gastrointestinal, hepatic, and neurologic systems, ICI ...
Kuchimanchi N   +3 more
europepmc   +2 more sources

Systematic differences between Cochrane and non-Cochrane meta-analyses on the same topic: a matched pair analysis [PDF]

open access: yes, 2015
BACKGROUND: Meta-analyses conducted via the Cochrane Collaboration adhere to strict methodological and reporting standards aiming to minimize bias, maximize transparency/reproducibility, and improve the accuracy of summarized data.
Ameli, Omid   +6 more
core   +4 more sources

Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis

open access: yesCritical Care Research and Practice, 2021
Purpose. To evaluate the efficacy and safety of midodrine use in intensive care units (ICU) to facilitate weaning off intravenous vasopressors (IVV). Methods.
Ahmad Al-Abdouh   +9 more
doaj   +1 more source

Use of midodrine in heart failure: a review

open access: yesAnnals of Medicine & Surgery, 2023
Heart failure is a global health concern, affecting millions of individuals worldwide. Midodrine, an alpha-1 receptor agonist, might be a potential treatment option for patients with heart failure and concurrent hypotension. This review provides a comprehensive summary of the existing literature on the use of midodrine in heart failure patients ...
Gautam, Sudarshan   +8 more
openaire   +2 more sources

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

open access: yes, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P   +21 more
core   +4 more sources

Home - About - Disclaimer - Privacy